Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting

Basit Öğe Kaydı
dc.authorid0000-0001-6034-8808en_US
dc.authorid0000-0002-9143-3893en_US
dc.authorid0000-0002-3586-9115en_US
dc.authorid0000-0002-3101-4742en_US
dc.authorid0000-0002-9886-2017en_US
dc.contributor.authorAltunan, Bengü
dc.contributor.authorEfendi, Hüsnü
dc.contributor.authorKöseoğlu, Mesrure
dc.contributor.authorTerzi, Murat
dc.contributor.authorKotan, Dilcan
dc.contributor.authorTamam, Yusuf
dc.contributor.authorÜnal, Aysun
dc.date.accessioned2023-08-18T06:15:11Z
dc.date.available2023-08-18T06:15:11Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalıen_US
dc.description.abstractBackground: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO- Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health. Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed. Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 ± 0.8 (1–4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY. Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.en_US
dc.identifier.citationAltunan, B., Ünal, A., Efendi, H., Köseoğlu, M., Terzi, M., Kotan, D. ve diğerleri. (2023).Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting. Multiple Sclerosis and Related Disorders, (77), 1-7.en_US
dc.identifier.doi10.1016/j.msard.2023.104880
dc.identifier.endpage7en_US
dc.identifier.issn2211-0348
dc.identifier.issue77en_US
dc.identifier.pmid37459716
dc.identifier.scopus2-s2.0-85165251046
dc.identifier.scopusqualityQ2
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2211034823003814?via%3Dihub
dc.identifier.urihttps://hdl.handle.net/11468/12503
dc.identifier.wosWOS:001039758400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTamam, Yusuf
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFollow-on drugen_US
dc.subjectGeneric fingolimoden_US
dc.subjectReal-world dataen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectSatisfactionen_US
dc.subjectAdherenceen_US
dc.titleUse of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical settingen_US
dc.titleUse of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Use of follow-on fingolimod for multiple sclerosis_ Analysis of effectiveness and patient reported outcomes in a real-world clinical setting.pdf
Boyut:
2.14 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu